159 related articles for article (PubMed ID: 19950283)
1. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.
Lapter S; Marom A; Meshorer A; Elmann A; Sharabi A; Vadai E; Neufeld A; Sztainberg Y; Gil S; Getselter D; Chen A; Mozes E
Arthritis Rheum; 2009 Dec; 60(12):3744-54. PubMed ID: 19950283
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase.
Rapoport MJ; Sharabi A; Aharoni D; Bloch O; Zinger H; Dayan M; Mozes E
Clin Immunol; 2005 Dec; 117(3):262-70. PubMed ID: 16257268
[TBL] [Abstract][Full Text] [Related]
4. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
5. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.
Mauermann N; Sthoeger Z; Zinger H; Mozes E
Clin Exp Immunol; 2004 Sep; 137(3):513-20. PubMed ID: 15320900
[TBL] [Abstract][Full Text] [Related]
6. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
Sharabi A; Lapter S; Mozes E
J Autoimmun; 2010 Mar; 34(2):87-95. PubMed ID: 19596183
[TBL] [Abstract][Full Text] [Related]
7. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations.
Elmann A; Sharabi A; Dayan M; Zinger H; Ophir R; Mozes E
Arthritis Rheum; 2007 Jul; 56(7):2371-81. PubMed ID: 17599765
[TBL] [Abstract][Full Text] [Related]
8. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E; Sharabi A
Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis.
Sharabi A; Haviv A; Zinger H; Dayan M; Mozes E
Clin Immunol; 2006 May; 119(2):146-55. PubMed ID: 16503419
[TBL] [Abstract][Full Text] [Related]
10. Induction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestations.
Telerman A; Lapter S; Sharabi A; Zinger H; Mozes E
J Neuroimmunol; 2011 Mar; 232(1-2):151-7. PubMed ID: 21129786
[TBL] [Abstract][Full Text] [Related]
11. A novel experimental approach in treating central nervous system lupus: kudos and kicks.
Sakic B
Arthritis Rheum; 2009 Dec; 60(12):3531-3. PubMed ID: 19950267
[No Abstract] [Full Text] [Related]
12. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
13. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation.
Luger D; Dayan M; Zinger H; Liu JP; Mozes E
J Clin Immunol; 2004 Nov; 24(6):579-90. PubMed ID: 15622442
[TBL] [Abstract][Full Text] [Related]
14. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.
Sharabi A; Dayan M; Zinger H; Mozes E
J Clin Immunol; 2010 Jan; 30(1):34-44. PubMed ID: 19756988
[TBL] [Abstract][Full Text] [Related]
15. IL-4Ralpha polymorphism in regulation of IL-4 synthesis by T cells: implication in susceptibility to a subset of murine lupus.
Shiroiwa W; Tsukamoto K; Ohtsuji M; Lin Q; Ida A; Kodera S; Ohtsuji N; Nakamura K; Tsurui H; Kinoshita K; Nishimura H; Shirai T; Hirose S
Int Immunol; 2007 Feb; 19(2):175-83. PubMed ID: 17189592
[TBL] [Abstract][Full Text] [Related]
16. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses.
Sela U; Dayan M; Hershkoviz R; Cahalon L; Lider O; Mozes E
Eur J Immunol; 2006 Nov; 36(11):2971-80. PubMed ID: 17051618
[TBL] [Abstract][Full Text] [Related]
17. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.
Sthoeger ZM; Sharabi A; Dayan M; Zinger H; Asher I; Sela U; Mozes E
Hum Immunol; 2009 Mar; 70(3):139-45. PubMed ID: 19280712
[TBL] [Abstract][Full Text] [Related]
18. Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells.
Luzina IG; Knitzer RH; Atamas SP; Gause WC; Papadimitriou JC; Sztein MB; Storrer CE; Handwerger BS
Arthritis Rheum; 1999 Mar; 42(3):561-8. PubMed ID: 10088780
[TBL] [Abstract][Full Text] [Related]
19. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
Enghard P; Langnickel D; Riemekasten G
Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
[TBL] [Abstract][Full Text] [Related]
20. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus.
Parameswaran R; Ben David H; Sharabi A; Zinger H; Mozes E
Clin Immunol; 2009 May; 131(2):223-32. PubMed ID: 19188092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]